BioSpace News Archive

As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or “bakeoff”) of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.

Currax Pharmaceuticals, LLC (“Currax”), a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines – both branded and generic – hosted a grand opening celebration of its new headquarters on September 29, 2021.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAV9 Titer Kit for rapid determination of physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy manufacturing.

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2021 financial results and respond to questions from financial analysts during the call.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), announces that greater than 50% of patients expected to complete the ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes have completed the full, 24-week, treatment period.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced final results from the Phase 3 PSOARING 3 long-term extension study of its investigational product tapinarof, a 1% once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults.

Abbott (NYSE: ABT) announced today the creation of the Abbott Center for Malnutrition Solutions, an innovation hub focused on reducing malnutrition around the world.

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients.

Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 – October 2, 2021.